nach oben

Cancer Microenvironment

Erschienen in:

01.04.2012

The Interrelating Dynamics of Hypoxic Tumor Microenvironments and Cancer Cell Phenotypes in Cancer Metastasis

verfasst von: Kai Bartkowiak, Sabine Riethdorf, Klaus Pantel

Erschienen in: Cancer Microenvironment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The interrelating dynamics of the primary tumor cells and their surrounding microenvironment might determine phenotypic characteristics of disseminated tumor cells and contribute to cancer metastasis. Cytoprotective mechanisms (e.g., energy metabolism control, DNA damage response, global translation control and unfolded protein response) exert selective pressure in the tumor microenvironment. In particular, adaptation to hypoxia is vital for survival of malignant cells in the tumor and at distant sites such as the bone marrow. In addition to the stress response, the ability of tumor cells to undergo certain cellular re-differentiation programmes like the epithelial-mesenchymal transition (EMT), which is linked to cancer stemness, appears to be important for successful cancer cell spread. Here we will discuss the selection pressures that eventually lead to the formation of overt metastases. We will focus the properties of the microenvironment including (i) metabolic and cytoprotective programs that ensure survival of disseminated tumor cells, (ii) blood vessel structure, and (iii) the hypoxia-normoxia switch as well as intrinsic factors affecting the evolvement of novel tumor cell populations.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456PubMedCrossRef

Ranganathan AC, Adam AP, Zhang L, Aguirre-Ghiso JA (2006) Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther 5:729–735PubMedCrossRef

Braun S, Kentenich C, Janni W, Hepp F et al (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18:80–86PubMed

Riethdorf S, Wikman H, Pantel K (2008) Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 123:1991–2006PubMedCrossRef

Solakoglu O, Maierhofer C, Lahr G, Breit E et al (2002) Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A 99:2246–2251PubMedCrossRef

Pantel K, Schlimok G, Angstwurm M, Weckermann D et al (1994) Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 3:165–173PubMedCrossRef

Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV et al (2000) Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 60:2541–2546PubMed

Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N et al (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153:865–873PubMedCrossRef

10.

Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572PubMedCrossRef

11.

Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329–340PubMedCrossRef

12.

Gatenby RA, Gillies RJ (2008) A microenvironmental model of carcinogenesis. Nat Rev Cancer 8:56–61PubMedCrossRef

13.

Korsching E, Jeffrey SS, Meinerz W, Decker T et al (2008) Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 61:553–560PubMedCrossRef

14.

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142PubMedCrossRef

15.

Bergfeld SA, DeClerck YA (2010) Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Canc Metastasis Rev 29:249–261.

16.

Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705–713PubMedCrossRef

17.

Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252PubMedCrossRef

18.

Agelopoulos K, Greve B, Schmidt H, Pospisil H et al (2010) Selective regain of egfr gene copies in CD44+/CD24−/low breast cancer cellular model MDA-MB-468. BMC Cancer 10:78.

19.

Dachs GU, Tozer GM (2000) Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 36:1649–1660PubMedCrossRef

20.

Coghlin C, Murray GI (2010) Current and emerging concepts in tumour metastasis. J Pathol 222:1–15.

21.

Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. J Mol Med 85:1301–1307PubMedCrossRef

22.

Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465PubMed

23.

Kallinowski F, Vaupel P, Runkel S, Berg G et al (1988) Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res 48:7264–7272PubMed

24.

Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8:967–975PubMedCrossRef

25.

Ward JP (2008) Oxygen sensors in context. Biochim Biophys Acta 1777:1–14PubMedCrossRef

26.

Noiva R (1999) Protein disulfide isomerase: the multifunctional redox chaperone of the endoplasmic reticulum. Semin Cell Dev Biol 10:481–493PubMedCrossRef

27.

Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270PubMed

28.

Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437–443PubMedCrossRef

29.

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732PubMedCrossRef

30.

Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187–197PubMedCrossRef

31.

Graber TE, Holcik M (2007) Cap-independent regulation of gene expression in apoptosis. Mol Biosyst 3:825–834PubMedCrossRef

32.

Baird NA, Turnbull DW, Johnson EA (2006) Induction of the heat shock pathway during hypoxia requires regulation of heat shock factor by hypoxia-inducible factor-1. J Biol Chem 281:38675–38681PubMedCrossRef

33.

Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8:851–864PubMedCrossRef

34.

Baird SD, Turcotte M, Korneluk RG, Holcik M (2006) Searching for IRES. RNA 12:1755–1785PubMedCrossRef

35.

Rao RV, Peel A, Logvinova A, del Rio G et al (2002) Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett 514:122–128PubMedCrossRef

36.

Rzymski T, Harris AL (2007) The unfolded protein response and integrated stress response to anoxia. Clin Cancer Res 13:2537–2540PubMedCrossRef

37.

Connolly E, Braunstein S, Formenti S, Schneider RJ (2006) Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 26:3955–3965PubMedCrossRef

38.

Papandreou I, Krishna C, Kaper F, Cai D et al (2005) Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res 65:3171–3178PubMed

39.

Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995–4004PubMedCrossRef

40.

Zhong H, Chiles K, Feldser D, Laughner E et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545PubMed

41.

Pore N, Jiang Z, Shu HK, Bernhard E et al (2006) Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4:471–479PubMedCrossRef

42.

Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D (2001) Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 20:7624–7634PubMedCrossRef

43.

Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH et al (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14:34–44PubMed

44.

Klein CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9:302–312PubMedCrossRef

45.

Zhang XH, Wang Q, Gerald W, Hudis CA et al (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16:67–78PubMedCrossRef

46.

Pantel K, Schlimok G, Braun S, Kutter D et al (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419–1424PubMedCrossRef

47.

Hemsen A, Riethdorf L, Brunner N, Berger J et al (2003) Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer 107:903–909PubMedCrossRef

48.

Klein CA, Seidl S, Petat-Dutter K, Offner S et al (2002) Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20:387–392PubMedCrossRef

49.

Thurm H, Ebel S, Kentenich C, Hemsen A et al (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 9:2598–2604PubMed

50.

Talmadge JE (2007) Clonal selection of metastasis within the life history of a tumor. Cancer Res 67:11471–11475PubMedCrossRef

51.

Polyak K, Hahn WC (2006) Roots and stems: stem cells in cancer. Nat Med 12:296–300PubMedCrossRef

52.

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111PubMedCrossRef

53.

Berx G, Raspe E, Christofori G, Thiery JP, Sleeman JP (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24:587–597PubMedCrossRef

54.

Pantel K, Alix-Panabieres C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6:339–351PubMedCrossRef

55.

Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846PubMedCrossRef

56.

Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R et al (2007) Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25:4952–4960PubMedCrossRef

57.

Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12:895–904PubMedCrossRef

58.

Xie K, Huang S (2003) Regulation of cancer metastasis by stress pathways. Clin Exp Metastasis 20:31–43PubMedCrossRef

59.

Kingsley LA, Fournier PG, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6:2609–2617PubMedCrossRef

60.

Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA (2006) Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 66:1702–1711PubMedCrossRef

61.

Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516PubMedCrossRef

62.

Norton L, Massague J (2006) Is cancer a disease of self-seeding? Nat Med 12:875–878PubMedCrossRef

63.

Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9:274–284PubMedCrossRef

64.

Kim MY, Oskarsson T, Acharyya S, Nguyen DX et al (2009) Tumor self-seeding by circulating cancer cells. Cell 139:1315–1326PubMedCrossRef

65.

Aird WC (2007) Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100:158–173PubMedCrossRef

66.

Aird WC (2007) Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 100:174–190PubMedCrossRef

67.

Kopp HG, Avecilla ST, Hooper AT, Rafii S (2005) The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 20:349–356CrossRef

68.

Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M et al (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 100:7737–7742PubMedCrossRef

69.

Engelhardt B, Sorokin L (2009) The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 31:497–511PubMedCrossRef

70.

Andres AC, Djonov V (2010) The mammary gland vasculature revisited. J Mammary Gland Biol Neoplasia 15:319–328.

71.

Djonov V, Andres AC, Ziemiecki A (2001) Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microsc Res Tech 52:182–189PubMedCrossRef

72.

Silva AS, Gatenby RA, Gillies RJ, Yunes JA (2010) A quantitative theoretical model for the development of malignancy in ductal carcinoma in situ. J Theor Biol 262:601–613.

73.

Safali M, Karslioglu Y, Arpaci F, Kurt B, Gunhan O (2010) A distinct microvascular pattern accompanied by aggressive clinical course in breast carcinomas: a fact or a coincidence? Pathol Res Pract 206:93–97.

74.

Banerjee S, Dowsett M, Ashworth A, Martin LA (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4:536–550PubMedCrossRef

75.

Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273PubMedCrossRef

76.

Meng S, Tripathy D, Frenkel EP, Shete S et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152–8162PubMedCrossRef

77.

Muller V, Alix-Panabieres C, Pantel K (2010) Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer 46:1189–1197.

78.

Schardt JA, Meyer M, Hartmann CH, Schubert F et al (2005) Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8:227–239PubMedCrossRef

79.

Young SD, Marshall RS, Hill RP (1988) Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A 85:9533–9537PubMedCrossRef

80.

Rofstad EK, Gaustad JV, Egeland TA, Mathiesen B, Galappathi K (2010) Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer 127:1535–1546.

81.

Walenta S, Wetterling M, Lehrke M, Schwickert G et al (2000) High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60:916–921PubMed

82.

Freiberg RA, Krieg AJ, Giaccia AJ, Hammond EM (2006) Checking in on hypoxia/reoxygenation. Cell Cycle 5:1304–1307PubMedCrossRef

83.

Bindra RS, Gibson SL, Meng A, Westermark U et al (2005) Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 65:11597–11604PubMedCrossRef

84.

Kang MJ, Jung SM, Kim MJ, Bae JH et al (2008) DNA-dependent protein kinase is involved in heat shock protein-mediated accumulation of hypoxia-inducible factor-1alpha in hypoxic preconditioned HepG2 cells. FEBS J 275:5969–5981PubMedCrossRef

85.

Ameri K, Luong R, Zhang H, Powell AA et al (2010) Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 102:561–569.

86.

Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA et al (2009) Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 11:R84PubMedCrossRef

87.

Risom L, Lundby C, Thomsen JJ, Mikkelsen L et al (2007) Acute hypoxia and reoxygenation-induced DNA oxidation in human mononuclear blood cells. Mutat Res 625:125–133PubMedCrossRef

88.

Chen Y, Azad MB, Gibson SB (2009) Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ 16:1040–1052PubMedCrossRef

89.

Azad MB, Chen Y, Gibson SB (2009) Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 11:777–790PubMedCrossRef

90.

Pires IM, Bencokova Z, Milani M, Folkes LK et al (2010) Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 70:925–935.

91.

Chan N, Pires IM, Bencokova Z, Coackley C et al (2010) Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 70:8045–8054.

92.

Hammond EM, Dorie MJ, Giaccia AJ (2003) ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 278:12207–12213PubMedCrossRef

93.

Chow DC, Wenning LA, Miller WM, Papoutsakis ET (2001) Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 81:685–696PubMedCrossRef

94.

Muller V, Stahmann N, Riethdorf S, Rau T et al (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11:3678–3685PubMedCrossRef

95.

Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19:617–621PubMedCrossRef

96.

Cheang MCU, Voduc D, Bajdik C, Leung S et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376PubMedCrossRef

97.

Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83:249–289PubMedCrossRef

98.

Putz E, Witter K, Offner S, Stosiek P et al (1999) Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 59:241–248PubMed

99.

Kang Y, Siegel PM, Shu W, Drobnjak M et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549PubMedCrossRef

100.

Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11–24PubMedCrossRef

101.

Bocker W, Moll R, Poremba C, Holland R et al (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82:737–746PubMed

102.

Korsching E, Packeisen J, Agelopoulos K, Eisenacher M et al (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82:1525–1533PubMed

103.

Korsching E, Packeisen J, Liedtke C, Hungermann D et al (2005) The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 206:451–457PubMedCrossRef

104.

Shipitsin M, Polyak K (2008) The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 88:459–463PubMedCrossRef

105.

Trumpp A, Wiestler OD (2008) Mechanisms of disease: cancer stem cells–targeting the evil twin. Nat Clin Pract Oncol 5:337–347PubMed

106.

Clarke MF, Fuller M (2006) Stem cells and cancer: two faces of eve. Cell 124:1111–1115PubMedCrossRef

107.

Marotta LL, Polyak K (2009) Cancer stem cells: a model in the making. Curr Opin Genet Dev 19:44–50PubMedCrossRef

108.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988PubMedCrossRef

109.

Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23:7274–7282PubMedCrossRef

110.

Shipitsin M, Campbell LL, Argani P, Weremowicz S et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259–273PubMedCrossRef

111.

Haase VH (2009) Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease. Kidney Int 76:492–499PubMedCrossRef

112.

Lester RD, Jo M, Montel V, Takimoto S, Gonias SL (2007) uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 178:425–436PubMedCrossRef

113.

Helczynska K, Kronblad A, Jogi A, Nilsson E et al (2003) Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 63:1441–1444PubMed

114.

Tarin D, Thompson EW, Newgreen DF (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65:5996–6000, discussion 6000–5991PubMedCrossRef

115.

Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746PubMedCrossRef

116.

Brandt BH, Roetger A, Dittmar T, Nikolai G et al (1999) c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 13:1939–1949PubMed

117.

Dittmar T, Husemann A, Schewe Y, Nofer JR et al (2002) Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 16:1823–1825PubMed

118.

Tanaka H, Shirkoohi R, Nakagawa K, Qiao H et al (2006) siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer 118:1680–1691PubMedCrossRef

119.

Sleeman JP (2000) The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 157:55–81PubMedCrossRef

120.

van der Pluijm G (2011) Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 48:37–43.

121.

Mani SA, Guo W, Liao MJ, Eaton EN et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715PubMedCrossRef

122.

Kakarala M, Wicha MS (2008) Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813–2820PubMedCrossRef

123.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674.

124.

Roetger A, Merschjann A, Dittmar T, Jackisch C et al (1998) Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model. Am J Pathol 153:1797–1806PubMedCrossRef

125.

Feldner JC, Brandt BH (2002) Cancer cell motility–on the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res 272:93–108PubMedCrossRef

126.

Storci G, Sansone P, Trere D, Tavolari S et al (2008) The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 214:25–37PubMedCrossRef

127.

Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X et al (2007) Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53:537–539PubMedCrossRef

128.

Braun S, Hepp F, Sommer HL, Pantel K (1999) Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 84:1–5PubMedCrossRef

129.

Slade MJ, Payne R, Riethdorf S, Ward B et al (2009) Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer 100:160–166PubMedCrossRef

130.

Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S et al (2006) CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59PubMedCrossRef

131.

Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U et al (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11:8006–8014PubMedCrossRef

132.

Bartkowiak K, Wieczorek M, Buck F, Harder S et al (2009) Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile. J Proteome Res 8:2004–2014PubMedCrossRef

133.

Bartkowiak K, Effenberger KE, Harder S, Andreas A et al (2010) Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J Proteome Res 9:3158–3168.

134.

Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 104:5431–5436PubMedCrossRef

135.

Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P et al (2004) Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10:1392–1400PubMedCrossRef

136.

Bross ID, Viadana E, Pickren J (1975) Do generalized metastases occur directly from the primary? J Chronic Dis 28:149–159PubMedCrossRef

Titel: The Interrelating Dynamics of Hypoxic Tumor Microenvironments and Cancer Cell Phenotypes in Cancer Metastasis
verfasst von: Kai Bartkowiak
Sabine Riethdorf
Klaus Pantel
Publikationsdatum: 01.04.2012
Verlag: Springer Netherlands
Erschienen in: Cancer Microenvironment / Ausgabe 1/2012
Print ISSN: 1875-2292
Elektronische ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-011-0067-6

Springer Medizin

The Interrelating Dynamics of Hypoxic Tumor Microenvironments and Cancer Cell Phenotypes in Cancer Metastasis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts

Regulation of Epithelial-Mesenchymal Transition by Transmission of Mechanical Stress through Epithelial Tissues

Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment

Soiling the Seed: Microenvironment and Epithelial Mesenchymal Plasticity

Transforming Growth Factor-β1 (TGF-β1) Driven Epithelial to Mesenchymal Transition (EMT) is Accentuated by Tumour Necrosis Factor α (TNFα) via Crosstalk Between the SMAD and NF-κB Pathways

Adipocytes Promote B16BL6 Melanoma Cell Invasion and the Epithelial-to-Mesenchymal Transition

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie